An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma

U-H Mellqvist, C Paba-Prada, A Palumbo, Torben Plesner, P Sonneveld, P Voorhees, C Byrne, J Harmenberg, E Nordström, P. Richardson

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

OriginalsprogEngelsk
Publikationsdato2014
StatusUdgivet - 2014
BegivenhedAnnual Congress of the European Hematology Association - Milano, Italien
Varighed: 12. jun. 201415. jun. 2014
Konferencens nummer: 19

Konference

KonferenceAnnual Congress of the European Hematology Association
Nummer19
LandItalien
ByMilano
Periode12/06/201415/06/2014

Citationsformater

Mellqvist, U-H., Paba-Prada, C., Palumbo, A., Plesner, T., Sonneveld, P., Voorhees, P., Byrne, C., Harmenberg, J., Nordström, E., & Richardson, P. (2014). An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma. Abstract fra Annual Congress of the European Hematology Association, Milano, Italien.